Immix Biopharma, Inc. Cash Flow Statement

Cash Flow Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -1.15M-24.38M-8.23M-15.60M-21.70M
Depreciation and Depletion 0.00M0.00M0.00M0.01M0.03M
Share-based Compensation 0.22M0.62M2.57M3.02M
Gains from Investment Securities 0.02M
Cash from Operations -0.40M-1.59M-7.41M-11.37M-14.60M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.06M0.08M
Depreciation & Amortization (CF) 0.00M0.00M0.00M0.01M0.03M
Change in Working Capital
Change in Accured Expenses 0.10M0.12M1.13M2.43M4.40M
Change in Taxes -0.06M-0.10M0.24M0.89M0.97M
Investing Activities
Capital Expenditures 0.00M0.05M1.18M
Cash from Investing Activities -0.00M-0.05M-1.18M
Financing Activities
Other financing activities 0.22M0.52M1.94M2.39M
Debt Issuance and Repayment
Long-Term Debt Issuances 0.20M
Long-Term Debt Repayments 0.05M
Change in Capital Stock
Shares Issued 18.65M0.47M15.52M15.95M
Shares Repurchased 0.10M
Misc.
Cash from Financing Activities 18.85M3.23M15.46M15.95M
Exchange Rate Effect 0.06M-0.01M-0.03M0.03M-0.00M
Change in Cash -0.34M17.25M-4.21M4.07M0.17M
Free Cash Flow -0.40M-1.59M-7.41M-11.42M-15.77M
Net Cash Flow -0.40M17.26M-4.18M4.04M0.18M